tbuckley/cabot-search huggingface dataset:
Proleukin (aldesleukin, rhIL-2) immunotherapy in combination with rituximab following initial CHOP/rituximab treatment induces highly durable complete responses in a xenograft model of indolent B-cell Non-Hodgkin’s lymphoma
Authors: Daniel E. Lopes de Menezes, Kimberly Denis-Mize, Carla Heise, Arnold B. Gelb, Helen Ye, Yan Tang, John Kunich, Sandra Milan, Laurence Elias, Susan E. Wilson, Lea Aukerman, Bahija Jallal
Journal: Cancer Research (2005)

556  Although low grade lymphomas generally respond well to treatment with chemotherapeutic agents the disease typically follows a course of recurrent relapse associated with shorter remissions resulting in disease progression. Rituximab (R) treatment in combination with CHOP (Cyclophosphamide, C; Doxorubicin, H; Vincristine, O, Prednisone, P) has been reported to increase the overall response rate in low grade NHL (up to 95%), but most patients eventually relapse highlighting the need for additional innovative strategies to improve the durability of clinical responses. In two Phase I studies we have shown that Proleukin (aldesleukin, rhIL-2) can augment activity of rituximab via expansion and activation of NK cells to mediate antibody-dependent cellular cytotoxicity (ADCC; Gluck et al., 2004. Clin. Cancer Res.). In this preclinical study, we investigated the ability of Proleukin (IL-2) to enhance the overall tumor efficacy and durability of responses when administered in combination with rituximab following initial CHOP/R treatment in a Daudi xenograft model of low grade CD20+ B-cell lymphoma. CHOP/R was modeled on clinical dosage regimens and treatment commenced when tumors were established (150-200mm3). Treatment groups comprised either CHOP alone (C, 40 mg/kg, i.v; H, 3.3 mg/kg, i.v; O, 0.5 mg/kg, i.v all administered on Day 1 and P, 0.2 mg/kg, p.o., days 1-5) or a 4 week cycle of rituximab (R) alone (10 mg/kg, once weekly, i.p) starting day 1 or CHOP in combination with a 4 week cycle of rituximab. Proleukin treatment (1 mg/kg; s.c., thrice weekly) commenced either concomitantly on day 1 or one week later on day 8 for a total of 4 weeks. All treatments were well tolerated. CHOP/R significantly inhibited tumor growth (99% tumor growth inhibition, TGI; 5/10 CR) and was superior to either R (63% TGI, 1 CR) or CHOP (77% TGI, 1 CR) alone. Notably, the addition of Proleukin (IL-2) to CHOP/R commenced either on D1 or D8 induced substantial tumor regression with 7/10 and 9/10 CR respectively and was superior to CHOP/R (p 164 days) compared to CHOP/R alone (90 days). In summary, our preclinical findings indicate that CHOP/R followed by IL-2/R is safe, efficacious and is predicted to add benefit in delaying time to progression compared to CHOP or CHOP/R. The clinical utility of CHOP/R followed by IL-2/R remains to be evaluated.
An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)
Authors: Joselle Cook, Kah-Whye Peng, Thomas E. Witzig, Stephen Broski, Jose C. Villasboas, Jonas Paludo, Mrinal M. Patnaik, S. Vincent Rajkumar, Angela Dispenzieri, Nelson Leung, Francis K. Buadi, N. Nora Bennani, Stephen M. Ansell, Lianwen Zhang, Nandakumar Pakiriswamy, Baskar Balakrishnan, Bethany Brunton, Marissa Giers, Brenda F Ginos, Amylou C. Dueck, Susan M. Geyer, Morie A. Gertz, Rahma M Warsame, Ronald Go, Suzanne R. Hayman, David Dingli, Shaji Kumar, P. Leif Bergsagel, Wilson I Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Prashant Kapoor, Robert A. Kyle, Yi Lin, Mustaqeem A. Siddiqui, Amie Fonder, Miriam A. Hobbs, Yi L. Hwa, Stephen J. Russell, Martha Q. Lacy
Journal: Blood (2021)
Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome
Authors: Rachel Cusatis, Michael Martens, Ryotaro Nakamura, Corey Cutler, Wael Saber, Stephanie J. Lee, Brent R. Logan, Bronwen E. Shaw, Mary M. Horowitz, Kathryn E Flynn
Journal: Blood (2021)
Metabolic Dysfunction-Associated Fatty Liver Disease and Subsequent Development of Adverse Pregnancy Outcomes
Authors: Seung Mi Lee, Young Mi Jung, Eun Saem Choi, Soo Heon Kwak, Ja Nam Koo, Ig Hwan Oh, Byoung Jae Kim, Sun Min Kim, Sang Youn Kim, Gyoung Min Kim, Sae Kyung Joo, Bo Kyung Koo, Sue Shin, Errol R Norwitz, Chan-Wook Park, Jong Kwan Jun, Won Kim, Joong Shin Park
Journal: Clinical Gastroenterology and Hepatology (2021)
Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Authors: Alina Markova, Alexander Pan, Stephen Dusza, Arifa Chowdhury, Oluwaseun Kukoyi, Miguel-Angel Perales, Mario Lacouture, Susan Prockop, Doris M Ponce
Journal: Blood (2021)
Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax
Authors: Meghan C. Thompson, Lindsey E. Roeker, Catherine C. Coombs, Jeffrey L. Jensen, Manali Kamdar, Alan Skarbnik, John M. Pagel, Neil Bailey, Jeffrey J. Pu, Ryan Jacobs, Brian T. Hill, Danielle M. Brander, Mazyar Shadman, Chaitra S. Ujjani, Kristen E. Battiato, Celina J. Komari, Guilherme Sacchi De Camargo Correia, Julia H. Aronson, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Paul M. Barr, Craig A. Portell, Nicole Lamanna, Javier Pinilla-Ibarz, Andrew D. Zelenetz, Stephen J Schuster, John N. Allan, Toby A. Eyre, Anthony R. Mato
Journal: Blood (2021)
Pathways to mental health care in active military populations across the Five-Eyes nations: An integrated perspective
Authors: Deniz Fikretoglu, Marie-Louise Sharp, Amy B. Adler, Stéphanie Bélanger, Helen Benassi, Clare Bennett, Richard Bryant, Walter Busuttil, Heidi Cramm, Nicola Fear, Neil Greenberg, Alexandra Heber, Fardous Hosseiny, Charles W. Hoge, Rakesh Jetly, Alexander McFarlane, Joshua Morganstein, Dominic Murphy, Meaghan O'Donnell, Andrea Phelps, Don J. Richardson, Nicole Sadler, Paula P. Schnurr, Patrick Smith, Robert Ursano, Miranda Van Hooff, Simon Wessely, David Forbes, David Pedlar
Journal: Clinical Psychology Review (2021)

Military service is associated with increased risk of mental health problems. Previous reviews have pointed to under-utilization of mental health services in military populations. Building on the most recent systematic review, our narrative, critical review takes a complementary approach and considers research across the Five-Eyes nations from the past six years to update and broaden the discussion on pathways to mental healthcare in military populations. We find that at a broad population level, there is improvement in several indicators of mental health care access, with greater gains in initial engagement, time to first treatment contact, and subjective satisfaction with care, and smaller gains in objective indicators of adequacy of care. Among individual-level barriers to care-seeking, there is progress in improving recognition of need for care and reducing stigma concerns. Among organizational-level barriers, there are advances in availability of services and cultural acceptance of care-seeking. Other barriers, such as concerns around confidentiality, career impact, and deployability persist, however, and may account for some remaining unmet need. To address these barriers, new initiatives that are more evidence-based, theoretically-driven, and culturally-sensitive, are therefore needed, and must be rigorously evaluated to ensure they bring about additional improvements in pathways to care.
Novel Evidence That By Employing a Two-Step Differentiation Protocol in the Presence of UM171 and Nicotinamide Acid Human Very Small Embryonic like Stem Cells (VSELs) Differentiate into Functional Endothelial Cells (ECs)
Authors: Alison Domingues, Elisa Rossi, Kamila Bujko, Grégoire Detriche, Janina Ratajczak, Ulysse Richez, Adeline Blandinieres, Magda Kucia, David M Smadja, Mariusz Z Ratajczak
Journal: Blood (2021)
Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Authors: Carmelo Gurnari, Simona Pagliuca, Pedro H. Prata, Luiz Fernando Bazzo Catto, Lise Larcher, Marie Sebert, Vincent Allain, Bhumika J. Patel, Laila Terkawi, Andre Luiz Pinto, Mariana Carolina Beraldo Ignacio, Lucie Hernandez, Nathalie Dhedin, Sophie Caillat-Zucman, Emmanuelle Clappier, Flore Sicre de Fontbrune, Maria Teresa Voso, Valeria Visconte, Gerard Socié, Rodrigo T. Calado, Regis Peffault De Latour, Jean Soulier, Jaroslaw P. Maciejewski
Journal: Blood (2021)
Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series
Authors: Ranjit Nair, Nafis Deen, Sairah Ahmed, Roberto N. Miranda, Nathan H. Fowler, Luis Fayad, Raphael E Steiner, Fredrick B. Hagemeister, Maria Alma Rodriguez, Hun Ju Lee, Paolo Strati, Luis Malpica-Castillo, Dai Chihara, Preetesh Jain, Jillian R. Gunther, Christopher R. Flowers, L. Jeffrey Medeiros, Yago Nieto, Jeremy L. Ramdial, Sattva S. Neelapu, Loretta Nastoupil, Michael R Green, Michael Wang, Francisco Vega, Lei Feng, Swaminathan Padmanabhan Iyer, Jason R. Westin
Journal: Blood (2021)
Sars-Cov-2 Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria: An Italian Multicenter Survey
Authors: Juri Alessandro Giannotta, Bruno Fattizzo, Corrado Girmenia, Claudia Ielo, Elisabetta Metafuni, Adele Visentin, Paola Bianchi, Vincenzo Apolito, Eloise Beggiato, Eros Di Bona, Simona Sica, Anna Paola Iori, Wilma Barcellini
Journal: Blood (2021)
A Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19
Authors: Ruchi Patel, Ki-Hyun Kim, Yong Gu Lee, Puneeth Guruprasad, Soohwan Kim, Ji-Hyeon Choi, Sung-Min Kim, Gae-Baik Kim, Jong-Ho Lee, Hyun-Jong Lee, Ji-Ho Park, Guewha Lee, LeiGuang Cui, Min Yoon, Ki Hyun Kim, Soohyun Kim, In-Sik Hwang, Youngha Lee, Jong Seo Lee, Junho Chung, Marco Ruella
Journal: Blood (2021)
Cell-Free DNA Dynamic Concentration, CRP and LDH Pre-Infusion Are Predictors of Early Progression after CAR T-Cell Therapy in DLBCL Patients
Authors: Mariana Bastos Oreiro, Laura Sanz-Villanueva, Francisco Diaz Crespo, Rebeca Bailén, Gillen Oarbeascoa, Isabel Gomez, Diego Carbonell, María Chicano Lavilla, Paula Muñiz, Javier Menarguez, Jose L. Diez-Martin, Mi Kwon, Ismael Buño, Carolina Martínez-Laperche
Journal: Blood (2021)
A Novel Humanized Murine Model to Identify Neoantigen-Specific T Cells in CBFA2T3-GLIS2 Positive Acute Megakaryoblastic Leukemia
Authors: Elizabeth A. R. Garfinkle, Jeremy Chase Crawford, Anthony E. Zamora, Nathan P. Croft, Anthony W. Purcell, Anitria Cotton, Allison Kirk, Ching-Heng Chou, Paul G. Thomas, Tanja Andrea Gruber
Journal: Blood (2021)
Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)
Authors: Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, Alessandra Iurlo, Sara Galimberti, Antonella Gozzini, Luigiana Luciano, Fabio Stagno, Antonella Russo Rossi, Nicola Sgherza, Daniele Cattaneo, Corrado Zuanelli Brambilla, Cristina Marzano, Carmen Fava, Olga Mulas, Emanuele Cencini, Alessandro Gozzetti, Luca Puccetti, Monica Bocchia
Journal: Blood (2021)
Abstract PO-005: Proteome profiling of pancreatic ductal adenocarcinoma (PDAC) primary tumors in Caucasian, African American and Latinx patients
Authors: Henry C. H. Law, Andrea N. Riner, Jose G. Trevino, Nicholas T. Woods
Journal: Cancer Research (2021)

Abstract The clinical management of pancreatic ductal adenocarcinoma (PDAC) faces difficult challenges due to its aggressive metastatic potential, complex microenvironment, and lack of targeted therapies. Health disparities also exacerbate these challenges. For instance, African and African Americans have higher incidence rates and worse clinical outcomes than Whites even when socioeconomic and tumor stages are controlled. To advance the understanding of the biological differences across the racial groups, the PDAC primary tumors collected from 30 Caucasian, 12 African American (AA) and 3 Latinx patients were analyzed by quantitative proteomics. In collaboration with the IDeA National Resource for Quantitative Proteomics, 5820 proteins were identified and quantified using data-independent acquisition (DIA) in the tumor proteome. Comparing the Latinx and the Caucasian tumor proteome, 120 and 95 proteins were found up- and down-regulated in the Latinx proteome. Proteins involved in the fatty acid metabolism, urea cycle, bile acid and bile salt metabolism were found enriched among the upregulated proteins. 108 and 75 proteins were found up- and down-regulated in African American tumor proteome over the Caucasians. The 108 upregulated proteins were submitted for Reactome Pathway Analysis. Pathways such as the complement cascade, extracellular matrix organization and ECM proteoglycans were found enriched. Haptoglobin-related protein (HPR) was one of the 108 upregulated proteins in the AA tumor proteome, which is also observed at the transcript level in the TCGA data. The HPR is known for its trypanolytic function and gene amplifications are observed in those of African descent. HPR works with haptoglobin (HP) to clear the free hemoglobin in blood to prevent oxidative damage. We believe that the proteins overexpressed, and the biological processes activated are contributing to the PDAC disparities observed in the African descendants. Therefore, the characterization of the PDAC proteome is a valuable method to delineate the underlying molecular signatures that may contribute to the health disparities. Citation Format: Henry C. H. Law, Andrea N. Riner, Jose G. Trevino, Nicholas T. Woods. Proteome profiling of pancreatic ductal adenocarcinoma (PDAC) primary tumors in Caucasian, African American and Latinx patients [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-005.
Efficacy of Thrombopoietin Receptor Agonists in Evans Syndrome: An International Multicenter Experience
Authors: Nicola Cecchi, Juri Alessandro Giannotta, Andrea Patriarca, Andreas Glenthøj, Maria Eva Mingot, Frederick Chen, Silvia Cantoni, Dennis Lund Hansen, Marco Capecchi, Henrik Frederiksen, Tomas Jose Gonzalez-Lopez, Wilma Barcellini, Bruno Fattizzo
Journal: Blood (2021)
Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks
Authors: Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood (2021)
FP16.05 Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC
Authors: V. Velcheti, A.K. Ganti, A. Kumar, V. Patil, H. Grover, D. Watson, M. Sauban, R. S, A. Agrawal, P. Kumari, A. Pampana, N. Mundkur, S. Patel, C. Kumar, N. Palaniyeppa, Z. Husain, H. Azam, P. G, U. Mitra, Y. Ullal, A. Ghosh, A. Prakash, K. Basu, D. Lala, S. Kapoor, M. Castro
Journal: Journal of Thoracic Oncology (2021)
Effects of Oral Intake of Olive Leaf Extract on Hematological Parameters: A Double-Blinded, Randomized, Placebo-Controlled Trial in Progress
Authors: Farhana Ferdousi, Masud Alam, Risa Araki, Sofya Suidasari, Miki Yokozawa, Ken Yamauchi, Koichi Hashimoto, Rashidul Haque, Hiroko Isoda
Journal: Blood (2021)
Long-term prognosis and educational determinants of brain network decline in older adult individuals
Authors: Micaela Y. Chan, Liang Han, Claudia A. Carreno, Ziwei Zhang, Rebekah M. Rodriguez, Megan LaRose, Jason Hassenstab, Gagan S. Wig
Journal: Nature Aging (2021)

Older adults with lower education are at greater risk for dementia. It is unclear which brain changes lead to these outcomes. Longitudinal imaging-based measures of brain structure and function were examined in adult individuals (baseline age, 45-86 years; two to five visits per participant over 1-9 years). College degree completion differentiates individual-based and neighborhood-based measures of socioeconomic status and disadvantage. Older adults (~65 years and over) without a college degree exhibit a pattern of declining large-scale functional brain network organization (resting-state system segregation) that is less evident in their college-educated peers. Declining brain system segregation predicts impending changes in dementia severity, measured up to 10 years past the last scan date. The prognostic value of brain network change is independent of Alzheimer's disease (AD)-related genetic risk (
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Authors: Philippe Moreau, Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesus San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez-López, Surbhi Sidana, Lixia Pei, Danielle Trancucci, Raluca I. Verona, Suzette Girgis, Yunsi Olyslager, Mindy Jaffe, Clarissa M. Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Y. Krishnan
Journal: Blood (2021)
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Authors: Marco Valgimigli, Davide Cao, Dominick J. Angiolillo, Sripal Bangalore, Deepak L. Bhatt, Junbo Ge, James Hermiller, Raj R. Makkar, Franz-Josef Neumann, Shigeru Saito, Hector Picon, Ralph Toelg, Aziz Maksoud, Bassem M. Chehab, James W. Choi, Gianluca Campo, Jose M. De la Torre Hernandez, Vijay Kunadian, Gennaro Sardella, Holger Thiele, Olivier Varenne, Pascal Vranckx, Stephan Windecker, Yujie Zhou, Mitchell W. Krucoff, Karine Ruster, Yan Zheng, Roxana Mehran
Journal: Journal of the American College of Cardiology (2021)

The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown.The purpose of this analysis was to compare 1 vs 3 months of DAPT in HBR patients undergoing drug-eluting stent implantation.The XIENCE Short DAPT program comprised 3 prospective, multicenter, single-arm studies of HBR patients treated with a short DAPT course followed by aspirin monotherapy after PCI with a cobalt-chromium everolimus-eluting stent. In this exploratory analysis, patients who received 1-month DAPT (XIENCE 28 USA and 28 Global) were compared with those on 3-month DAPT (XIENCE 90) using propensity score stratification. Ischemic and bleeding outcomes were assessed between 1 and 12 months after index PCI.A total of 3,652 patients were enrolled and 1,392 patients after 1-month DAPT and 1,972 patients after 3-month DAPT were eligible for the analyses. The primary endpoint of all-cause mortality or myocardial infarction was similar between the 2 groups (7.3% vs 7.5%; difference -0.2%; 95% CI: -2.2% to 1.7%; P = 0.41). The key secondary endpoint of BARC (Bleeding Academic Research Consortium) type 2-5 bleeding was lower with 1-month DAPT compared with 3-month DAPT (7.6% vs 10.0%; difference -2.5%; 95% CI: -4.6% to -0.3%; P = 0.012). Major BARC type 3-5 bleeding did not differ at 12 months (3.6% vs 4.7%; difference -1.1%; 95% CI: -2.6% to 0.4%; P = 0.082), but was lower with 1-month DAPT at 90 days (1.0% vs 2.1%; P = 0.015).Among HBR patients undergoing PCI, 1 month of DAPT, compared with 3 months of DAPT, was associated with similar ischemic outcomes and lower bleeding risk. (XIENCE 90 Study; NCT03218787; XIENCE 28 USA Study; NCT03815175; XIENCE 28 Global Study; NCT03355742).
Factor IX Expression within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients with Severe Hemophilia B: Long-Term Follow-up Study of the B-Amaze Program
Authors: Pratima Chowdary, Susan Shapiro, Mike Makris, Gillian Evans, Sara Boyce, Kate Talks, Gerry Dolan, Ulrike Reiss, Mark Phillips, Anne Riddell, Maria Rita Peralta, Michelle Quaye, Ted Tuddenham, Alison Long, Julie Krop, Amit Nathwani
Journal: Blood (2021)
Attracting consultants and GPs to rural and coastal communities
Authors: Peter William Sellar
Journal: BMJ (2021)

Bird draws attention to health issues in isolated coastal towns around Britain, referencing the chief medical officer’s recent Health in Coastal Communities report.1 Coastal communities are usually isolated from main rail routes, motorways, and airports so miss out on major investment and employment opportunities.

West Cumbrian coastal towns, for example, are one hour from the M6 and over 2.5 hours from regional airports and tertiary referral centres in Newcastle and Manchester. …
Chronic Lymphocytic Leukemia Cells with Mutated Nfkbie Are Positively Selected By Microenvironmental Signals and Display Reduced Sensitivity to Ibrutinib Treatment
Authors: Alice Bonato, Riccardo Bomben, Supriya Chakraborty, Giulia Felician, Claudio Martines, Antonella Zucchetto, Annalisa Chiarenza, Giovanni Del Poeta, Roberto Marasca, Agostino Tafuri, Luca Laurenti, Aleksandar J. Dimovski, Valter Gattei, Dimitar G Efremov
Journal: Blood (2021)
Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program
Authors: Florent Malard, Michael Loschi, Thomas Cluzeau, Anne Huynh, Sarah Guenounou, Cecile Borel, Faezeh Legrand, Angela Granata, Raynier Devillier, Valerio Maisano, Leonardo Magro, Corentin Orvain, Amandine Charbonnier, Marta Panz-Klapuch, Miroslaw Markiewicz, Deborah Desmier, Niels Moya, Jean-Baptiste Mear, Faustine Lhomme, Caroline Le Jeune, Jérôme Cornillon, Christine Robin, Ernst Holler, Etienne Daguindau, Karin Bilger, Maria Vehreschild, Amandine Le Bourgeois, Patrice Chevallier, Hélène Labussière-Wallet, Delphine Martineau, Marie-Anne Couturier, Claude-Eric Bulabois, Helene Lanic, Vincent Camus, Sylvain Chantepie, Patrice Ceballos, Cyrielle Gasc, Emilie Plantamura, Mohamad Mohty
Journal: Blood (2021)
MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
Authors: Erin Brooks, Ashley Spahn, Stephanie Waldvogel, Alan Howard, Merav Bar, Brandi Bratrude, Saurabh Chhabra, William Clark, Suman Ranjan Das, Mary M. Horowitz, Robert R. Jenq, Richard J. Jones, John E. Levine, Brent R. Logan, Hemant S. Murthy, Armin Rashidi, Marcie L. Riches, Mary Mansour Riwes, Karamjeet S. Sandhu, Anthony D. Sung, Monzr M. Al Malki, Lyndsey Runaas, Hany Elmariah, Andrew R. Rezvani, Mahasweta Gooptu, Javier Bolaños-Meade, Shernan G Holtan, Wael Saber, Mehdi Hamadani, Leslie S Kean, Miguel-Angel Perales, Ami S. Bhatt
Journal: Blood (2021)